ISRCTN12908996进行中（未招募）2 期
Interleukin-1 receptor antagonist treatment for refractory complex regional pain syndrome
niversity of Liverpool0 个研究点目标入组 26 人开始时间: 2021年9月1日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 26
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •Current inclusion criteria as of 30/01/2024 (updated 13/02/2024):
- •1. A diagnosis of CRPS I or II according to the Budapest research criteria at the time of the assessment for this study
- •2. First documented diagnosis of Budapest CRPS by a healthcare professional not less than 18 months and not longer than 15 years before the screening assessment. A valid documented diagnosis must either include the term 'Budapest CRPS', or must include the term 'CRPS' and in addition documentation of the presence of signs and symptoms which allow making the Budapest diagnosis from the notes.
- •3. Pain intensity average 6 or greater on a 0-10-point numerical rating scale (NRS) over a minimum of seven consecutive daily entries prior to baseline (0 day) visit, with no single value below 5.
- •4. Completed a previous course of appropriate specialised physiotherapy
- •5. Poor response or intolerance to at least one anti-neuropathic pain medication such as tricyclic antidepressants or gabapentinoids.
- •6. If a woman of childbearing potential (WOCBP), to be willing to confirm the use of adequate birth control during the trial period unless pregnancy is impossible
- •7. Fertile male patients to be using contraception for the duration of therapy if sexually active with a female partner.
- •8. Age 18 years and over
- •9. Written and informed consent obtained from patient and agreement of patient to comply with the requirements of the study
- •Previous inclusion criteria as of 07/03/2023:
- •1. A diagnosis of CRPS I or II according to the Budapest research criteria at the time of the assessment for this study
- •2. First documented diagnosis of Budapest CRPS by a healthcare professional not longer than 15 years before the screening assessment. A valid documented diagnosis must either include the term 'Budapest CRPS', or must include the term 'CRPS' and in addition documentation of the presence of signs and symptoms which allow making the Budapest diagnosis from the notes.
- •3. Pain intensity average 6 or greater on a 0-10-point numerical rating scale (NRS) over a minimum of seven consecutive daily entries prior to baseline (0 day) visit, with no single value below 5.
- •4. Completed a previous course of appropriate specialised physiotherapy
- •5. Poor response to anti-neuropathic pain medications- either unacceptable side effects or inadequate pain relief (Clinicians discretion)
- •6. If a woman of childbearing potential (WOCBP), to be willing to confirm the use of adequate birth control during the trial period unless pregnancy is impossible
- •7. Fertile male patients to be using contraception for the duration of therapy if sexually active with a female partner
- •8. Age 18 years and over
- •9. Written and informed consent obtained from patient and agreement of patient to comply with the requirements of the study.
- •Original inclusion criteria:
- •1. Diagnosis of complex regional pain syndrome I or II according to the Budapest research criteria
- •2. Disease duration of 18 months to 10 years
- •3. Average pain intensity of =6 on a 10-point numerical rating scale (NRS) over a minimum of 7 consecutive daily entries prior to baseline (0 day) visit, with no single value below
- •4. Completed a previous course of appropriate specialised physiotherapy
- •5. Poor response to anti-neuropathic pain medications- either unacceptable side effects or inadequate pain relief (Clinicians discretion)
- •6. If a woman of childbearing potential (WOCBP), to be willing to confirm the use of adequate birth control during the trial
排除标准
- •Current exclusion criteria as of 30/01/2024 (updated 13/02/2024):
- •1. Medical conditions that in the opinion of the study investigator would make it unsafe for participation or can adversely affect outcomes
- •2. Co-existing pain that in the view of the study doctor may make assessment of outcomes related to refractory moderate to severe CRPS unreliable
- •3. Ongoing relevant litigation where its conclusion is imminent during the course of the study
- •4. Medical Contraindications to anakinra such as moderate/severe or progressive renal impairment (CLCR <60 ml/min or eGFR <60 ml/min/1.73m2 or end stage renal disease, including dialysis), or hepatic impairment (defined as any value of transaminases, ?-glutamyl transpeptidase, or bilirubin greater than
- •2 times the upper normal limit) or hypersensitivity to anakinra or any of its excipients or to E.coli-derived proteins.
- •5. Previous use of anakinra
- •6. Current or recent (within 6 months) use of other immunosuppressants or biologics
- •7. Neutropenia defined as Absolute Neutrophil Count< 1.5 x 109/L
- •8. Requirement to receive a live vaccine during the trial duration.
- •9. Active or latent Tuberculosis infection
- •10. HIV, Hepatitis B or C carrier
- •11. Brittle asthma
- •12. Active malignancy or malignancy within 2 years
- •13. Ongoing alcohol or drug misuse at registration
- •14. Psychiatric or other mental health disorder which in the opinion of the study investigator may interfere with successful study participation
- •15. Commencing new therapy for refractory moderate to severe CRPS that may alter the outcome of the trial drug; this includes new pain
- •management program treatment. Equally patients who have completed a pain management program within the past 3 months
- •16. Subject is pregnant or breastfeeding, inadequate birth control, or the possibility of pregnancy during the study.
- •17. Patients who have a spinal cord or dorsal root ganglion stimulator whose average pain is less than 6 out of 10 when the stimulator is on.
- •Previous exclusion criteria as of 07/03/2023:
- •1. Medical conditions that, in the opinion of the study investigator, would make it unsafe for participation or can adversely affect outcomes
- •2. Co-existing pain that, in the view of the study doctor, may make an assessment of outcomes related to refractory moderate to severe CRPS unreliable
- •3. Ongoing relevant litigation where its conclusion is imminent during the course of the study
- •4. Medical Contraindications to anakinra such as moderate/severe or progressive renal impairment (eGFR<60ml/min/1.73m²), hepatic impairment (defined as any value of transaminases, ?-glutamyl transpeptidase, or bilirubin greater than 2 times the upper normal limit) or hypersensitivity to anakinra or any of its excipients or to E.coli-derived proteins.
- •5. Previous use of anakinra
- •6. Current or recent (within 6 months) use of other immunosuppressants or biologics
- •7. Neutropenia defined as Absolute Neutrophil Count <1.5 x 10e9/l
- •8. Requirement to receive a live vaccine during the trial duration
- •9. Active or latent tuberculosis infection
- •10. HIV, Hepatitis B or C carrier
- •11. Brittle asthma
- •12. Active malignancy or malignancy within 2 years
- •13. Ongoing alcohol or drug misuse at registration
- •14. Psychiatric or other mental health disorder which in the opinion of the study investigator may interfere with successful study participation
- •15. Commencing new therapy for refractory moderate to severe CRPS that may alter the outcome of the trial drug; this includes new pain managem
研究者
相似试验
已完成
1 期
An open-label study of the cerebrospinal fluid pharmacokinetics of intravenous Kineret® (recombinant methyionyl human interleukin-1 receptor antagonist [r-metHuIL-1RA]) in patients with subarachnoid haemorrhageISRCTN45931429Salford Royal Foundation Hospital Trust (UK)100
尚未招募
不适用
Treatment with recombinant human Interleukin 1 receptor antagonist (Anakinra) in patients with anaplastic thyroid cancer: a proof of concept studyNL-OMON22269Radboud UMC Nijmegen, The Netherlands10
进行中（未招募）
1 期
Treatment with Anakinra for patients with anaplastic thyroid cancerAnaplastic Thyroid CarcinomaEUCTR2017-003028-59-NLRadboud University Medical Centre10
已完成
不适用
Treatment with Recombinant human Interleukin 1 receptor antagonist (Anakinra) in patients with Anaplastic Thyroid Cancer: a proof of concept studyNL-OMON46644Radboud Universitair Medisch Centrum10
进行中（未招募）
1 期
BLOC-ICH; Could a new treatment improve recovery for patients who have had an intracerebral haemorrhageintracerebral haemorrhageMedDRA version: 20.0 Level: LLT Classification code 10022753 Term: Intracerebral haemorrhage System Organ Class: 100000004852EUCTR2018-000249-38-GBniversity of Manchester80